Friends, Colleagues, and Shareholders,
One of the most repeated phrases we’ve heard in the last six months is, “We live in very strange times,” and it’s true. The COVID-19 virus infections continue to rise and social distancing has made us feel more alone than ever before. Yet through it all, we continue to persevere. Our company, Mydecine Innovations Group, has been a shining light as we continue to pave the path forward as an emerging biopharma company with a focus on psychedelics. By staying true to our mission of discovering solutions to mental health disorders and with our advancements of alternative nature-sourced medicine, we’re now putting together the final pieces that have the potential to help millions live a better life. Here are just some of our recent company highlights...
Over the last six months, we have grown by leaps and bounds, acquiring strategic assets and launching vital clinical trials around the world. We’ve acquired NeuroPharm, because their management is committed to launching global clinical trials with its corresponding psychedelic-assisted therapy to treat traumatic disorders observed in veterans, EMS personnel, and first responders. To date, the clinical trial calendar includes test sites in Canada, the United States, and Europe. Additional clinical trial sites are under evaluation for Australia and South East Asia.
More great news for our shareholders is that we have established a highly sophisticated research and development branch with Applied Pharmaceutical Innovation (“API”), launched a new telehealth mobile app, and have expanded our IP portfolio.
API is a not-for-profit, translational and commercial drug development institution hosted at the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, and provides us direct access to a multi-million dollar research facility with an entire team of world-renowned researchers exclusively dedicated to our projects. As a whole, API provides the expertise, services, and infrastructure of a fully established pharmaceutical environment.
It is no surprise that our partnership with API provides exceptional capacity for us. API has opened the doorway for Mydecine’s ability to considerably speed-up and streamline our product development. This should ultimately translate into higher consistent revenues for the company.
Our IP portfolio is rapidly growing. Did you know that Mydecine Innovations Group has announced several recent actions regarding the expansion of its Intellectual Property Portfolio (IPP)? These include the filing of multiple new patent applications with the United States Patent and Trademark Office (USPTO), acquisition of patents, trademarks, and internet domains pertaining to Mydecine Innovations Group. These actions further strengthen Mydecine’s intellectual property and technology portfolio, as well as support our strategic growth and position us as a leader in the field of psychedelics and its corresponding therapies.
Mydecine also has the legal ability to produce scalable, naturally-derived CGMP psilocybin from whole-mushroom extraction as well as other isolated active compounds.
Mydecine is equipped with a special Health Canada Schedule I Controlled Drugs and Substances Dealer’s License, allowing Mydecine legal range to focus on its core fundamentals.
As a result, Mydecine not only has the ability to just extract whole-mushroom psilocybin, but we can also cultivate, process, research, sell, and export this psychedelic fungi as well. This gives the company a significant advantage and places us years ahead of competition. It is also worth noting that Mydecine has also conducted the world’s first clinical trials for the safety and efficacy of psilocybin for treating veterans suffering with PTSD (Post-Traumatic Stress Disorder) in close collaboration with Dr. Vermetten out of Leiden University.
As we look back on all we’ve accomplished in the last six months during some of the craziest times we have ever faced, we still continue to charge harder than ever before, and look forward to the coming calendar year. Our company stands poised to make significant progress in 2021 and we look forward to sharing our latest updates with you each month as Mydecine continues to evolve. We may face uncertain times, but with your support, Mydecine Innovations Group will continue to stay focused to achieve great success.
Have a Wonderful Thanksgiving,
